Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics

Core Insights - Crown Laboratories has successfully acquired Revance Therapeutics, reinforcing its position as a leading and innovative player in the aesthetics and skincare industry [1][2] - The acquisition was completed through a tender offer at a price of $3.65 per share, with approximately 82.0% of Revance's outstanding shares validly tendered [2] - Following the acquisition, Revance's common stock will be delisted from NASDAQ and deregistered under the Securities Exchange Act of 1934 [2] Company Overview - Crown is a privately held, fully integrated global skincare company focused on developing a diverse portfolio of aesthetic and therapeutic skincare products [4] - The company has been recognized on the Inc. 5000 Fastest Growing Privately Held Companies List for eleven consecutive years and has expanded its distribution to over 50 countries [4]